Prevalence of Hyperglycemia Among Adults with Newly Diagnosed HIV/AIDS in China

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2013 Feb 12

PMID 23394285

Citations 11

Authors

Yinzhong Shen

Zhenyan Wang

Li Liu

Renfang Zhang

Yufang Zheng

Hongzhou Lu

Affiliations

Soon will be listed here.

Abstract

Background: The prevalence of hyperglycemia among HIV-infected persons who are not receiving antiretroviral therapy is unknown. We conducted a cross-sectional survey to estimate the prevalence of hyperglycemia among Chinese adults with newly diagnosed HIV/AIDS.

Methods: Two thousand and six newly diagnosed HIV/AIDS patients from 10 provinces and municipalities in China were selected during 2009 to 2010. After an overnight fast, serum samples were collected to measure glucose concentrations. Demographics and medical histories were recorded. Factors associated with the presence of diabetes were analysed by logistic regression.

Results: Among the 2006 patients, 75.67% were male. Median age was 40 years (range: 18-86 years). 19.99% had hyperglycemia, 9.47% had impaired fasting glucose (IFG) and 10.52% had diabetes. The prevalences of hyperglycemia, of IFG and of diabetes were 21.54%, 10.28% and 11.27% among men and 15.16%, 6.97% and 8.20% among women, respectively. The prevalence of diabetes increased with increasing age (7.00%, 13.36% and 21.21% among patients who were 18-40, 40-60, and ≥60 years of age respectively) and with decreasing CD4 count (6.74%, 8.45%, 9.69%, and 12.66% among patients with CD4 count of ≥350, 200-350, 50-200, and < 50/mm3 respectively). The prevalence of diabetes was higher among ethnic minority patients than among the Han patients (14.37% versus 9.24%). The logistic analysis showed that older age, lower CD4 count and minority ethnicity were significantly associated with an increased risk of diabetes.

Conclusions: Hyperglycemia is highly prevalent among Chinese adults with newly diagnosed HIV/AIDS. Older age, lower CD4 count and minority ethnicity are associated with increased risk of diabetes. All newly diagnosed HIV/AIDS individuals should be routinely evaluated for hyperglycemia.

Citing Articles

Prevalence and factors associated with hyperglycemia among persons living with HIV/AIDS on dolutegravir-based antiretroviral therapy in Uganda.

Byereta L, Olum R, Mutebi E, Kalyesubula R, Kagimu M, Meya D Ther Adv Infect Dis. 2024; 11:20499361241272630.

PMID: 39286262 PMC: 11403689. DOI: 10.1177/20499361241272630.

Serum Lipid Profiles, Blood Glucose, and High-Sensitivity C-Reactive Protein Levels Among People Living with HIV Taking Dolutegravir and Ritonavir-Boosted Atazanavir-Based Antiretroviral Therapy at Jimma University Medical Center, Southwest....

Waritu N, Nair S, Birhan B, Adugna T, Awgichew G, Jemal M HIV AIDS (Auckl). 2024; 16:17-32.

PMID: 38369986 PMC: 10873129. DOI: 10.2147/HIV.S430310.

The prevalence of hyperglycemia and its impact on mortality among people living with HIV in Georgia.

Borkowska T, Chkhartishvili N, Karkashadze E, Chokoshvili O, Gabunia P, Sharvadze L PLoS One. 2022; 17(10):e0276749.

PMID: 36301817 PMC: 9612544. DOI: 10.1371/journal.pone.0276749.

Derangement of Liver Enzymes, Hyperglycemia, Anemia, and Associated Factors among HIV-Infected Patients Treated with Tenofovir Disoproxil Fumarate-Based Regimen in Ethiopia: A Prospective Cohort Study.

Yazie T Biomed Res Int. 2021; 2021:6613519.

PMID: 34222476 PMC: 8221861. DOI: 10.1155/2021/6613519.

HIV and Aging in Mainland China: Implications for Control and Prevention Research.

He N, Ding Y, Li J, Yuan S, Xu L, Qiao S Curr HIV/AIDS Rep. 2019; 16(6):439-447.

PMID: 31773404 DOI: 10.1007/s11904-019-00473-2.

References

Worm S, De Wit S, Weber R, Sabin C, Reiss P, El-Sadr W . Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). Circulation. 2009; 119(6):805-11. PMC: 2715841. DOI: 10.1161/CIRCULATIONAHA.108.790857. View

Hasse B, Ledergerber B, Furrer H, Battegay M, Hirschel B, Cavassini M . Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2011; 53(11):1130-9. DOI: 10.1093/cid/cir626. View

Ledergerber B, Furrer H, Rickenbach M, Lehmann R, Elzi L, Hirschel B . Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis. 2007; 45(1):111-9. DOI: 10.1086/518619. View

Zhang F, Dou Z, Ma Y, Zhang Y, Zhao Y, Zhao D . Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. Lancet Infect Dis. 2011; 11(7):516-24. DOI: 10.1016/S1473-3099(11)70097-4. View

David M, Hornung R, Fichtenbaum C . Ischemic cardiovascular disease in persons with human immunodeficiency virus infection. Clin Infect Dis. 2001; 34(1):98-102. DOI: 10.1086/324745. View

Brown T, Cole S, Li X, Kingsley L, Palella F, Riddler S . Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005; 165(10):1179-84. DOI: 10.1001/archinte.165.10.1179. View

Dube M . Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis. 2000; 31(6):1467-75. DOI: 10.1086/317491. View

Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J . Prevalence of diabetes among men and women in China. N Engl J Med. 2010; 362(12):1090-101. DOI: 10.1056/NEJMoa0908292. View

Gougeon M, Penicaud L, Fromenty B, Leclercq P, Viard J, Capeau J . Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations. Antivir Ther. 2004; 9(2):161-77. View

10.

Currier J, Lundgren J, Carr A, Klein D, Sabin C, Sax P . Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation. 2008; 118(2):e29-35. PMC: 5153327. DOI: 10.1161/CIRCULATIONAHA.107.189624. View

11.

Hardy H, Esch L, Morse G . Glucose disorders associated with HIV and its drug therapy. Ann Pharmacother. 2001; 35(3):343-51. DOI: 10.1345/aph.10044. View

12.

De Wit S, Sabin C, Weber R, Worm S, Reiss P, Cazanave C . Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care. 2008; 31(6):1224-9. PMC: 2746200. DOI: 10.2337/dc07-2013. View

13.

Lichtenstein K, Delaney K, Armon C, Ward D, Moorman A, Wood K . Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr. 2003; 32(1):48-56. DOI: 10.1097/00126334-200301010-00007. View

14.

Melzi S, Carenzi L, Cossu M, Passerini S, Capetti A, Rizzardini G . Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems. Cholesterol. 2011; 2010:271504. PMC: 3065849. DOI: 10.1155/2010/271504. View

15.

Mauss S, Corzillius M, Wolf E, Schwenk A, Adam A, Jaeger H . Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment. HIV Med. 2002; 3(1):49-55. DOI: 10.1046/j.1464-2662.2001.00100.x. View

16.

Blanco F, San Roman J, Vispo E, Lopez M, Salto A, Abad V . Management of metabolic complications and cardiovascular risk in HIV-infected patients. AIDS Rev. 2010; 12(4):231-41. View

17.

Capeau J, Bouteloup V, Katlama C, Bastard J, Guiyedi V, Salmon-Ceron D . Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. AIDS. 2011; 26(3):303-14. DOI: 10.1097/QAD.0b013e32834e8776. View